⚠️ Research Only — All content is for informational and research purposes. Not medical advice. Read full disclaimer

Desmopressin

Also known as: DDAVP, Minirin, 1-deamino-8-D-arginine vasopressin

Desmopressin is a synthetic analog of vasopressin (antidiuretic hormone) that increases water reabsorption in the kidneys and enhances blood clotting by releasing factor VIII and von Willebrand factor. This peptide hormone analog demonstrates significantly longer duration of action than natural vasopressin due to structural modifications that prevent enzymatic breakdown.

Last updated: February 23, 2026Reviewed by: Endocrinology Research Team

Desmopressin is a 1069.2 g/mol research peptide. Desmopressin is a synthetic analog of vasopressin (antidiuretic hormone) that increases water reabsorption in the kidneys and enhances blood clotting by releasing factor VIII and von Willebrand factor. This peptide hormone analog demonstrates significantly longer duration of action than natural vasopressin due to structural modifications that prevent enzymatic breakdown.

Also called: DDAVP, Minirin, 1-deamino-8-D-arginine vasopressin

1069.2 g/mol

Molecular Weight

Daltons

3

Strong Evidence

benefits

4

Studies Cited

peer-reviewed

10-40

Typical Dose

mcg

Overview

Desmopressin represents a breakthrough in vasopressin replacement therapy, engineered with specific amino acid modifications that extend its biological activity. The peptide works by binding to V2 receptors in the kidney's collecting duct, triggering insertion of aquaporin-2 water channels that dramatically increase water reabsorption. Beyond its antidiuretic effects, desmopressin stimulates release of stored factor VIII and von Willebrand factor from endothelial cells, making it valuable for certain bleeding disorders. The synthetic nature eliminates the vasoconstrictive effects seen with natural vasopressin, providing targeted therapeutic action without cardiovascular complications.

Key Takeaways: Desmopressin

  • Strongest evidence supports Desmopressin for diabetes insipidus management and hemophilia a and von willebrand disease
  • Research doses typically range from 10 to 40 mcg via intranasal
  • 3 benefits with strong evidence, 3 moderate, 0 preliminary
  • Half-life: 1.5-2.5 hours (nasal), 3.5 hours (subcutaneous)
  • 4 cited research studies in this guide

Mechanism of Action

Desmopressin selectively binds to V2 receptors in renal collecting duct cells, activating adenylyl cyclase and increasing cAMP levels. This cascade promotes insertion of aquaporin-2 water channels into the apical membrane, enhancing water reabsorption. Simultaneously, desmopressin triggers release of factor VIII and von Willebrand factor from Weibel-Palade bodies in endothelial cells through V2 receptor activation, improving hemostatic function.

Research Benefits

Desmopressin at a Glance

Primary mechanism:

Desmopressin selectively binds to V2 receptors in renal collecting duct cells, activating adenylyl cyclase and increasing cAMP levels.

Top researched benefits:
Diabetes Insipidus ManagementHemophilia A and von Willebrand DiseaseNocturnal Enuresis ControlPerioperative Bleeding ReductionNocturia TreatmentPlatelet Function Enhancement

Diabetes Insipidus Management

Strong Evidence

Effectively replaces deficient ADH in central diabetes insipidus, reducing urine output from 10-15 liters to normal levels by restoring kidney water reabsorption capacity.

Hemophilia A and von Willebrand Disease

Strong Evidence

Increases factor VIII levels 3-5 fold and von Willebrand factor by 2-4 fold, providing hemostatic support for mild to moderate bleeding disorders without blood product exposure.

Nocturnal Enuresis Control

Strong Evidence

Reduces nighttime urine production in children and adults with primary nocturnal enuresis, achieving dry nights in 60-70% of patients through enhanced overnight antidiuresis.

Perioperative Bleeding Reduction

Moderate Evidence

Decreases surgical blood loss by 20-40% in procedures involving patients with mild bleeding disorders or those requiring enhanced hemostasis.

Nocturia Treatment

Moderate Evidence

Reduces nighttime urination frequency in adults with nocturnal polyuria, improving sleep quality and reducing falls in elderly populations.

Platelet Function Enhancement

Moderate Evidence

Improves platelet aggregation and adhesion through increased von Willebrand factor availability, particularly beneficial in uremic bleeding and certain platelet disorders.

Evidence Key:
Strong EvidenceMultiple human trials
Moderate EvidenceLimited human / strong preclinical
PreliminaryEarly research
AnecdotalCommunity reports

Research Dosing Protocols

Research Purposes Only: All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.

Research ProtocolDose RangeRoute
Central diabetes insipidus1040 mcgintranasal
Hemophilia A/vWD0.30.4 mcg/kgsubcutaneous
Nocturnal enuresis2040 mcgintranasal
Nocturia25100 mcgsublingual

Frequency

1-3 times daily depending on indication

Timing

Morning and evening for diabetes insipidus; bedtime for enuresis

Cycle Length

Continuous therapy with periodic assessment

Research Notes

  • 1Start with lowest effective dose and titrate based on response
  • 2Monitor serum sodium levels regularly during initiation
  • 3Fluid restriction may be necessary to prevent hyponatremia
  • 4Sublingual tablets provide more consistent absorption than nasal spray

Reconstitution Guide

Standard Reconstitution

Vial Size

4 mg

Bacteriostatic Water

1 mL

Concentration

40 mcg

per 0.1 mL (10 units)

Step-by-Step Guide

1

Gather Materials

Desmopressin vial, bacteriostatic water, alcohol swabs, insulin syringes.

2

Equilibrate Temperature

Remove the vial from storage and allow it to reach room temperature (5-10 minutes).

3

Sanitize

Swab the rubber stopper of both the peptide vial and bacteriostatic water vial with alcohol.

4

Draw Water

Draw 1 mL of bacteriostatic water into a syringe.

5

Add Water to Vial

Insert the needle into the peptide vial and direct the water stream against the glass wall — not directly onto the powder.

6

Mix Gently

Swirl the vial gently until the powder is fully dissolved. Never shake. The solution should be clear and colorless.

7

Store Properly

Refrigerate at 2-8°C. 24 months unopened, 48 hours after reconstitution.

Storage Temperature

2-8°C

Shelf Life

24 months unopened, 48 hours after reconstitution

Important Notes

  • Injectable formulation ready-to-use, no reconstitution needed
  • Nasal spray requires gentle priming before first use
  • Protect from light and extreme temperatures
  • Single-use vials should be discarded after opening

Safety & Side Effects

Reported Side Effects

  • !Hyponatremia (water intoxication)
  • !Headache
  • !Nausea and vomiting
  • !Nasal congestion and irritation
  • !Flushing
  • !Abdominal cramps
  • !Vulval pain (in women)
  • !Injection site reactions
  • !Dizziness
  • !Fatigue

Potential Interactions

  • Carbamazepine, chlorpropamide, NSAIDs - increase hyponatremia risk
  • Lithium - may reduce antidiuretic effect
  • Tricyclic antidepressants - enhance antidiuretic action
  • Loop diuretics - may antagonize effects
  • Corticosteroids - may increase fluid retention risk

Important: Side effects and interactions listed here are compiled from published research and community reports. This is not a complete list. No formal drug interaction studies have been conducted for most research peptides. Always consult a qualified healthcare provider.

Research Studies

The following studies are referenced in this profile. PubMed IDs are provided where available for independent verification.

Efficacy and safety of desmopressin in nocturnal enuresis

Glazener CM, Evans JH2002Cochrane Database Syst Rev
PMID: 12137681

Systematic review of 47 trials showing desmopressin reduces wet nights during treatment but relapse rates are high after discontinuation.

Desmopressin for treatment of nocturia: a systematic review and meta-analysis

Ebell MH, Radke T, Gardner J2014J Urol
PMID: 24518775

Meta-analysis demonstrating significant reduction in nocturnal voids and improved quality of life in adults with nocturia.

DDAVP in hemophilia A: a double-blind, controlled, crossover study

Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A1977Thromb Haemost
PMID: 337533

Landmark study establishing desmopressin's efficacy in raising factor VIII levels in mild hemophilia A patients.

Long-term safety of desmopressin in central diabetes insipidus

Robinson AG, Verbalis JG2003Endocrinol Metab Clin North Am

Comprehensive review of long-term desmopressin therapy showing excellent safety profile with appropriate monitoring.

Note: This is not an exhaustive list of all published research. Studies are selected for relevance and quality. Click PubMed IDs to verify sources independently. Inclusion does not imply endorsement of the peptide for any clinical use.

Frequently Asked Questions

Desmopressin is a synthetic analog of vasopressin with structural modifications that make it longer-acting and more selective for V2 receptors. Unlike natural vasopressin, desmopressin has minimal vasoconstrictive effects and lasts 8-12 hours versus 10-20 minutes for vasopressin.

Desmopressin begins working within 15-30 minutes when given by injection, and 30-60 minutes when taken intranasally or sublingually. Peak effects occur at 1-4 hours depending on the route of administration.

Yes, hyponatremia is the most serious side effect of desmopressin, especially with excessive fluid intake. Regular sodium monitoring is essential, and patients should follow fluid restriction guidelines provided by their healthcare provider.

Desmopressin is generally safe for long-term use when properly monitored. Regular assessment of sodium levels, kidney function, and clinical response is necessary to ensure continued safety and efficacy.

Take the missed dose as soon as you remember, unless it's almost time for the next dose. Never double the dose. For diabetes insipidus, missing doses can lead to increased urination and thirst, so maintaining consistent dosing is important.

Yes, desmopressin is approved for nocturnal enuresis in children over 5 years old. However, careful monitoring for hyponatremia is crucial in pediatric patients, and fluid restriction before bedtime is typically recommended.

Desmopressin can interact with several medications including NSAIDs, certain antidepressants, and diuretics. These interactions may increase the risk of hyponatremia or alter the effectiveness of desmopressin.

Store desmopressin in the refrigerator at 2-8°C (36-46°F). Nasal sprays can be stored at room temperature for up to 3 weeks after opening. Protect from light and never freeze the medication.

⚠️

Research & Educational Use Only

All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.

The information presented here is compiled from published research studies and is intended for informational purposes only. Individual results may vary. Always consult with a licensed healthcare provider.